Amgen Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +25

Amgen Is Up 51% in a Year. Is It Too Late to Buy? - TIKR.com

AI-generated analysis

📈 AMGN shares closed at $432.42 near an all-time high, trading above the $388 average analyst price target after a 51% gain over the past year.

💰 Q2 revenue reached $10.05 billion, crossing the $10 billion mark for the first time, with adjusted earnings of $6.29 beating consensus by nearly 12%.

🚀 Management raised full-year guidance for both revenue and earnings, driven by six growth drivers that now account for roughly 70% of product sales.

📊 The stock trades at 18.4x forward earnings, a premium valuation near the high end of its recent range compared to peers like AbbVie (16.8x) and Biogen (16.5x).

💉 Repatha revenue rose 37% to $953 million, while EVENITY grew 38% and TEZSPIRE increased 42%, diversifying the portfolio away from biosimilar erosion.

⚠️ Merck received FDA approval for Enlicitide, an oral PCSK9 inhibitor that directly targets Repatha, introducing a competitive risk to Amgen's largest franchise.

🔒 AMGN disclosed a cybersecurity incident where patient health data was exfiltrated from third-party cloud storage, though the company expects no material financial impact.

📉 TIKR's model projects a base case return of roughly 14% total by 2030, or about 3% annually, plus a dividend yield near 2.3%.

🔮 The upcoming November 2 earnings report will be a critical test for whether growth drivers can outpace legacy declines and defend market share.

📉 Analyst sentiment is mixed with 16 Hold ratings against 10 Buy/Outperform, and the average price target remains below the current market price.

Bullish Signals
  • Amgen reported Q2 revenue of $10.05 billion, crossing the $10 billion threshold for the first time with adjusted earnings of $6.29 beating consensus by nearly 12%.
  • Management raised full-year guidance for both revenue and earnings, signaling confidence in the company's growth trajectory despite high valuations.
  • The portfolio mix has improved significantly as six growth drivers now supply close to 70% of product sales, reducing reliance on the denosumab franchise.
  • Repatha revenue surged 37% to $953 million, driven by expanding use in primary prevention among high-risk patients and increased prescribing per physician.
  • The Rare Disease portfolio is showing exceptional strength with UPLIZNA growing 90% across three approved indications.
  • Non-GAAP operating margins are holding near 45% to 46% as Horizon acquisition amortization rolls off, supporting strong profitability.
Risk Factors
  • The stock trades at 18.4x forward earnings, above the consensus analyst price target of $388, leaving little margin of safety for execution errors.
  • Merck's FDA approval of Enlicitide, an oral PCSK9 inhibitor, poses a direct competitive threat to Repatha, Amgen's largest single product.
  • The company disclosed a cybersecurity incident involving the exfiltration of patient health information and proprietary data from third-party cloud storage.
  • Legacy franchises including Prolia, XGEVA, and Enbrel are declining, which constrains overall revenue growth to low-single-digit projections.
  • Analyst sentiment is cautious with 16 Hold ratings versus only 10 Buy/Outperform, and the average price target remains below the current market price.
Full Analysis
Amgen Inc. (AMGN) shares closed near an all-time high of $432.42 on August 28, trading above the consensus analyst price target after a strong Q2 report. The company reported quarterly revenue of $10.05 billion, marking the first time it crossed the $10 billion threshold, with adjusted earnings of $6.29 beating estimates by nearly 12%. Management raised full-year guidance for both revenue and earnings, driven by a portfolio where six growth drivers now supply close to 70% of product sales. The stock's valuation has expanded significantly, trading at approximately 18.4x forward earnings, which is near the high end of its recent range and above key peers like AbbVie and Biogen. While the company benefits from a robust pipeline including Repatha, EVENITY, and TEZSPIRE, the market has largely priced in these growth drivers. Analysts note that with low-single-digit revenue growth modeled for the future, the stock offers limited cushion against potential setbacks or slower-than-expected legacy franchise declines. Key risks include competition from Merck's newly approved oral PCSK9 inhibitor, Enlicitide, which targets Amgen's largest product, Repatha. Although Amgen's Chief Commercial Officer argues the new drug has different labeling and food restrictions, the approval introduces a variable that could pressure Repatha's market share. Additionally, the company disclosed a cybersecurity incident involving the exfiltration of patient health information from third-party cloud storage, though it stated this would not materially impact its financial condition. Looking ahead, TIKR's valuation model projects Amgen at around $495 by 2030, implying a low-single-digit annual return plus a dividend yield near 2.3%. The upcoming November 2 earnings report will be critical to test whether the six growth drivers can continue to outpace legacy declines and if Repatha can maintain its share against new competition. At current prices, the margin of safety is considered gone, requiring flawless execution to justify the premium valuation.